Q1 EPS Estimate for Kyverna Therapeutics Lowered by Analyst

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Research analysts at HC Wainwright lowered their Q1 2025 earnings estimates for shares of Kyverna Therapeutics in a research report issued to clients and investors on Thursday, April 3rd. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.87) per share for the quarter, down from their previous forecast of ($0.72). HC Wainwright currently has a "Neutral" rating and a $4.00 target price on the stock. The consensus estimate for Kyverna Therapeutics' current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Kyverna Therapeutics' Q2 2025 earnings at ($0.89) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.94) EPS and FY2025 earnings at ($3.61) EPS.

Separately, Morgan Stanley lowered their price target on Kyverna Therapeutics from $40.00 to $20.00 and set an "overweight" rating on the stock in a report on Tuesday, April 1st. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $18.33.

Kyverna Therapeutics Price Performance

Shares of KYTX stock traded up $0.19 during trading on Monday, reaching $2.06. The company had a trading volume of 167,487 shares, compared to its average volume of 429,661. The firm's 50 day simple moving average is $2.51 and its two-hundred day simple moving average is $3.78. Kyverna Therapeutics has a one year low of $1.79 and a one year high of $24.59. The company has a market capitalization of $89.02 million, a PE ratio of -0.59 and a beta of 2.57.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.01).

Institutional Trading of Kyverna Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers lifted its holdings in shares of Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company's stock worth $61,000 after buying an additional 5,694 shares during the last quarter. Wellington Management Group LLP raised its stake in Kyverna Therapeutics by 16.7% during the 4th quarter. Wellington Management Group LLP now owns 274,414 shares of the company's stock valued at $1,026,000 after purchasing an additional 39,291 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in Kyverna Therapeutics in the 4th quarter valued at $125,000. Squarepoint Ops LLC acquired a new stake in Kyverna Therapeutics in the 4th quarter worth $43,000. Finally, Two Sigma Advisers LP increased its holdings in shares of Kyverna Therapeutics by 375.1% during the 4th quarter. Two Sigma Advisers LP now owns 80,290 shares of the company's stock worth $300,000 after purchasing an additional 63,390 shares during the period. Institutional investors own 18.08% of the company's stock.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.